Sunday - October 11, 2026

the Nontuberculous Mycobacteria Infections Treatment Market Size in the 7MM was more than USD 750 million in 2025 and It is projected to grow at a CAGR of 12.6% by 2036

The Nontuberculous Mycobacterial market report delivers important insights into ongoing research on Nontuberculous Mycobacterial Drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 08, 2026, DelveInsight’s “Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast – 2036” … Continue reading →

Multiple Sclerosis Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The Multiple Sclerosis clinical trial analysis report delivers important insights into ongoing research on 75+ pipeline Multiple Sclerosis Drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 08, 2026, DelveInsight’s “Multiple Sclerosis Pipeline Insight 2026” report provides … Continue reading →

Myelodysplastic Syndrome Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 120+ Leading Players Wheeling the Therapeutics Landscape

The Myelodysplastic Syndrome clinical trial analysis report delivers important insights into ongoing research on 120+ pipeline Myelodysplastic Syndrome Drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 08, 2026, DelveInsight’s “Myelodysplastic Syndrome Pipeline Insights 2026” report provides … Continue reading →

Startup Equity Compensation Mistakes Are Creating Costly 409A Problems, K-38 Consulting Finds

K-38 Consulting warns that startup equity compensation mistakes can create costly 409A compliance problems, particularly when option grants occur after financing events but before a refreshed valuation. The firm recommends coordinating valuation timelines, financing calendars, equity grants, and documentation to … Continue reading →